

1 **Creatine utilization as a sole nitrogen source in *Pseudomonas putida* KT2440 is**  
2 **transcriptionally regulated by CahR**

3

4

5 Running title: Regulation of *Pseudomonas putida* creatine metabolism

6

7 Lauren A. Hinkel<sup>1,2,#</sup>, Graham G. Willsey<sup>1,2,@</sup>, Sean M. Lenahan<sup>2</sup>, Korin Eckstrom<sup>1</sup>,  
8 Kristin C. Schutz<sup>1</sup>, and Matthew J. Wargo<sup>1</sup>, \*

9

10 1 – Department of Microbiology and Molecular Genetics, University of Vermont Lerner  
11 College of Medicine, Burlington, VT 05405

12 2 – Cellular, Molecular, and Biomedical Sciences Graduate Program, University of  
13 Vermont, Burlington, VT 05405

14

15 # Current address: Department of Biology, Rutgers Camden, Camden, NJ 08182

16

17 @ Current address: Division of Infectious Diseases, Wadsworth Center, New York State  
18 Department of Health, Albany, NY 12208

19

20 \* Corresponding Author

## 21 ABSTRACT

22 Glutamine amidotransferase-1 domain-containing AraC-family transcriptional  
23 regulators (GATRs) are present in the genomes of many bacteria, including all  
24 *Pseudomonas* species. The involvement of several characterized GATRs in amine-  
25 containing compound metabolism has been determined, but the full scope of GATR ligands  
26 and regulatory networks are still unknown. Here, we characterize *Pseudomonas putida*'s  
27 detection of the animal-derived amine compound, creatine, a compound particularly  
28 enriched in muscle and ciliated cells by a creatine-specific GATR, PP\_3665, here named  
29 CahR (Creatine amidohydrolase Regulator). *cahR* is necessary for transcription of the gene  
30 encoding creatinase (*PP\_3667/creA*) in the presence of creatine and is critical for *P.*  
31 *putida*'s ability to utilize creatine as a sole source of nitrogen. The CahR/creatine regulon  
32 is small and electrophoretic mobility shift demonstrates strong and specific CahR binding  
33 only at the *creA* promoter, supporting the conclusion that much of the regulon is dependent  
34 on downstream metabolites. Phylogenetic analysis of *creA* orthologs associated with *cahR*  
35 orthologs highlights a strain distribution and organization supporting likely horizontal gene  
36 transfer, particularly evident within the genus *Acinetobacter*. This study identifies and  
37 characterizes the GATR that transcriptionally controls *P. putida* metabolism of creatine,  
38 broadening the scope of known GATR ligands and suggesting GATR diversification  
39 during evolution of metabolism for aliphatic nitrogen compounds.

40

41

## 42 INTRODUCTION

43 Like many primarily soil-dwelling microbes, the Gram-negative bacterium  
44 *Pseudomonas putida* has evolved a vast and diverse array of transport and metabolic

45 machinery to fuel its organoheterotrophic lifestyle <sup>(1)</sup>. Within the rhizosphere, fast and  
46 efficient adjustment to the surrounding environment ensures successful acquisition of  
47 essential nutrients and activation of stress responses that are crucial to *P. putida*'s survival  
48 <sup>(2)</sup>. Effective response to the extracellular environment is partly afforded by the large  
49 number of transcription regulatory proteins encoded by the *P. putida* genome. About 2%  
50 of the predicted genes in the 6.15 Mbp *P. putida* KT2440 genome contain a conserved  
51 AraC-type DNA-binding Helix-Turn-Helix motif, characteristic of many catabolism-  
52 related transcription regulators <sup>(3)</sup>. These AraC-family transcription regulators control a  
53 large number of metabolic processes within *P. putida*, although for many, the cognate  
54 inducing ligands and target regulons have not been identified.

55         Creatine is an amine compound found primarily in animal tissues where it serves  
56 to buffer charging of high-energy carriers during rapid ADP to ATP conversion. It is  
57 particularly abundant in tissues that require large pools of ATP and ADP for periods of  
58 intense energy expenditure, such as fast twitch skeletal muscle and ciliated cells <sup>(4)</sup>.  
59 Metabolism of dietary creatine in animals occurs via partial metabolism and modification  
60 by gut-residing bacteria creating 1-methylhydantoin, a metabolite that is not easily  
61 metabolized by the body and can lead to tissue inflammation. To prevent creation and  
62 accumulation of 1-methylhydantoin, the major avenue of creatine homeostasis in animals  
63 is the excretion of creatine and creatinine in the urine, where it can be used by soil  
64 microbes. *Pseudomonas* species have been observed to metabolize creatine and creatinine,  
65 as well as the microbial breakdown product, 1-methylhydantoin <sup>(4), (5), (6), (7), (8), (9), (10), (11),</sup>  
66 <sup>(12)</sup>. The products of creatine and creatinine metabolism by *Pseudomonas* vary depending  
67 on the specific degradation pathway used, which is species and sometimes strain  
68 dependent. For creatinine, the process often begins with breakdown of creatinine to

69 creatine by a creatininase (creatinine amidohydrolase), though there are alternate pathways  
70 of metabolism. Creatine is then further metabolized to sarcosine and urea by creatinase  
71 (creatine amidohydrolase), and sarcosine is then converted to glycine and formaldehyde  
72 by the tetrameric sarcosine oxidase (SoxB DAG) (**Fig. 1A**), or to methylamine by sarcosine  
73 reductase and/or glycine reductase <sup>(4), (5), (13), (14)</sup>.

74 Production of creatinase is inducible in *P. putida* when the bacterium is supplied  
75 with creatine as the sole carbon or nitrogen source, but the induction mechanism is  
76 currently unknown <sup>(8)</sup>. *P. putida* PP\_3665 encodes an AraC-type transcription regulator  
77 convergently transcribed with an operon containing the creatinase gene, *creA* (**Fig. 1B**).  
78 Among characterized *Pseudomonas* genomes, only a few, including particular strains of *P.*  
79 *putida* and *P. resinovorans*, maintain likely orthologs of both the creatinase gene and the  
80 associated AraC-family transcription regulator in a similar syntenic arrangement <sup>(3)</sup>. Both  
81 of these species of *Pseudomonas* are present primarily in soils and are active participants  
82 in the rhizobiome, i.e. bacteria within the rhizosphere. It is within the rhizosphere that *P.*  
83 *putida* most likely encounters creatine, as creatine and its anhydrous form, creatinine, are  
84 present in soils, deposited via animal urine or feces as well as through animal tissue  
85 degradation <sup>(15), (16), (17), (18)</sup>.

86 Here, we describe identification of a regulator, PP\_3665, required for  
87 transcriptional induction of creatinase in *P. putida* in response to creatine and utilization of  
88 creatine as a sole nitrogen source, leading us to name PP\_3665 as the Creatine  
89 amidohydrolase Regulator, CahR.

90

## 91 MATERIALS AND METHODS

### 92 Bacterial Strains and Growth Conditions

93 *Pseudomonas putida* strain KT2440 and mutants made from this parent strain were  
94 grown at 30 °C shaking (170 rpm) in morpholinopropanesulfonic acid (MOPS) media <sup>(19)</sup>  
95 with modification we previously reported <sup>(20)</sup>, supplemented with 25 mM pyruvate, 5 mM  
96 arginine, and 20 µg/ml gentamicin when needed for plasmid maintenance. *Escherichia coli*  
97 strains DH5α and S17λpir, used for cloning and conjugation with *P. putida*, respectively,  
98 and *E. coli* strain T7 used for recombinant protein expression, were maintained in lysogeny  
99 broth (LB), Lennox formulation, supplemented with 7 µg/ml gentamicin or 150 µg/ml  
100 carbenicillin as appropriate. *E. coli* strains were grown at 37°C with shaking (170 rpm).

101

### 102 Construction of the *P. putida* ΔPP\_3665 deletion strain and complementation construct

103 A 980 base pair (bp) fragment upstream of the coding region of *cahR* was amplified  
104 with primers PP3665KO\_F1\_HindIII (5'-AAGCTTCGGGATCGTTCCAGATGCGT-3')  
105 and PP3665KO\_R1 (5'-GATCCAGGTGCTGCCCGATGCCA-3'). A 1 kb fragment  
106 downstream of the coding region of *cahR* was amplified with primers PP3665KO\_F2 (5'-  
107 GTTGGGTCAGGTATTGGCATTG-3') and PP3665KO\_R2\_EcoRI (5'-  
108 GAATCCCGAGGCGGAAAACCCCTGT-3'). The two fragments flanking the *cahR*  
109 coding region were spliced together via splice-overlap extension (SOE) PCR using primers  
110 PP3665KO\_F1\_HindIII and PP3665KO\_R2\_EcoRI, digested, and ligated into similarly  
111 cut plasmid pMQ30<sup>(21)</sup> containing a gentamicin resistance cassette for initial selection and  
112 the *sacB* gene for counter selection. pMQ30 containing the flanking regions of *cahR*  
113 (pMQ30:*cahR*-KO) was maintained in *E. coli* strain DH5α, and transformed into *E. coli*  
114 S17λpir for conjugation with *P. putida*. Single crossover integrants were selected by

115 gentamicin resistance (50 µg/ml) and double crossover to deletion or revertant was carried  
116 out on LB agar with no salt and amended with 10% sucrose, as previously described<sup>(22)</sup>,  
117 <sup>(23)</sup>, to yield an unmarked deletion of *PP\_3665/cahR* in *P. putida* strain KT2440 (strain  
118 LAH111). Deletion or reversion was determined using primers PP3665 KO screen F (5'-  
119 ATTCACCACCATCGGCCTT-3') and PP3665 KO screen R (5'-  
120 AGCGGTAGCCTTTGAGCAAT-3'), which yields a 3.3 kb product in WT and a 2 kb  
121 product in the deletion strain.

122 *cahR* complementation in the  $\Delta cahR$  strain was achieved by plasmid expressed  
123 *cahR*. Briefly, the coding region of *cahR* and divergently transcribed gene *pssA* (to ensure  
124 inclusion of the full coding region and promoter region of *cahR*) were amplified using  
125 primers PP\_3665-EXP-F\_EcoRI (5'-ATAGAATTCGACATCAATGCGCGGTGC-3')  
126 and PP\_3665-EXP-R-HindIII (5'-AAAAAGCTTCTGCACTGGCTTCTTCTCAC-3').  
127 The ~2.5 kb fragment was digested with the aforementioned enzymes and ligated into the  
128 similarly cut pMQ80 plasmid. The resulting pMQ80:*pssA/cahR* complementing plasmid  
129 was then electroporated into *P. putida* KT2440  $\Delta cahR$  as previously described <sup>(22)</sup>.

130

### 131 Nitrogen source growth assays

132 *P. putida* KT2440 wild type and  $\square cahR$  strains carrying the pMQ80 empty vector,  
133 and *P. putida* KT2440  $\Delta cahR$  complemented with pMQ80:*pssA/cahR* were grown  
134 overnight at 30 °C shaking in 1x MOPS buffer amended with 25 mM pyruvate, 5 mM  
135 arginine, and 20 µg/ml gentamicin. Cells from overnight culture were collected by  
136 centrifugation, washed with 1x MOPS media lacking nitrogen (MOPS no nitrogen), and  
137 adjusted in 1x MOPS no nitrogen to an optical density at 600 nm (OD<sub>600</sub>) of 0.5. These  
138 normalized cell suspensions were added to pre-warmed 1x MOPS no nitrogen media

139 amended with 20 mM pyruvate, 20 µg/ml gentamicin, and 2 mM of one of the following  
140 nitrogen sources: choline, creatine, creatinine, sarcosine, or arginine. A control for residual  
141 growth in media lacking a nitrogen source was also included. Cells were added to each  
142 condition to a final optical density at 600 nm (OD<sub>600</sub>) of 0.05 in a 500 µl final volume in  
143 wells of a 48-well plate. Cultures were incubated at 30 °C with horizontal shaking at 170  
144 rpm for 18 hours. The optical densities of cultures were measured at times 0 hours and 18  
145 hours using a Synergy H1 plate reader (BioTek, Winooksi, VT). Growth was reported as  
146 the net growth of each strain amended with a nitrogen source after subtraction of the optical  
147 density in the 0 mM nitrogen condition, as there is always a small amount of residual  
148 growth from stored intracellular nitrogen.

149

150 *cahR*-dependent transcriptional induction assays and *PP\_3667/creA* promoter mapping

151 Transcriptional reporter fusions of the full *creA* promoter, -10 bp to -195 bp from the  
152 predicted *creA* transcriptional start site, and a promoter truncation including -10 bp to -169  
153 bp from the predicted *creA* transcriptional start site, to the coding region of GFP were  
154 constructed following a protocol for creation of recombinant plasmids similar to that  
155 described by Bryksin and Matsumura<sup>(24)</sup>. The full promoter region of *creA* was amplified  
156 using *PP\_3667*PromF (5'- CGGGTACCGAGCTCGTTCAGGCCGGCCGC-3') and  
157 *PP\_3667*PromR (5'-TAAGATTAGCGGATCAGACTTTGTGGC-3') primers, and the -  
158 169 truncation fragment was amplified using primers *PP\_3667*PromF (5'-  
159 CGGGTACCGAGCTCGTTCAGGCCGGCCGC-3') and *PP\_3667*Prom-169R (5'-  
160 CGGGTACCGAGCTCGTCATGGAGCTGGACC-3'). Primers for amplification of the  
161 full and -169 truncated *creA* promoters contain 5'-regions complementary to the sequence  
162 upstream of GFP's coding region on plasmid pMQ80. The promoter fragments flanked

163 with pMQ80 complementary ends were mixed with plasmid pMQ80, and the mixtures  
164 were denatured, annealed and amplified via PCR to allow for insertion of the promoter  
165 region upstream of pMQ80's GFP. Insertion of the *creA* promoter fragments resulted in  
166 deletion of pMQ80's NheI and EcoRI restriction sites, so the amplified plasmid pool was  
167 digested with EcoRI and NheI to cull pMQ80 that did not incorporate the *creA* promoters.  
168 Following separation and purification of the circular plasmid via gel electrophoresis, the  
169 *creA* promoter-containing plasmids were transformed into *E. coli* DH5 $\alpha$ . The -56 *creA*  
170 promoter truncation was constructed via three sequential PCRs, using the reverse primer  
171 pMQ80\_GFP\_R (5'-TCAGGCTGAAAATCTTCTC-3') and the following forward  
172 primers for a 5'-extension of GFP including the truncated promoter of *creA*; PP3667-56\_1  
173 (5'- CTTCTCAGGCGGCCGGCCTGAACCGAGCTCGGTACCCG-3'), PP\_3667-56\_2  
174 (5'-GTCGGTTCTGTTGCAATGCTTCTCAGGCGGCCGGCC-3'), and PP\_3667-  
175 56\_3\_BamHI (5'-AATGGATCCGTGTCCTCGTTCGGTTCTG-3'). This -56 *creA*  
176 promoter-GFP fusion fragment was digested with restriction enzymes BamHI and HindIII  
177 and ligated into similarity cut pMQ80. The -80 *creA* promoter-GFP fusion fragment was  
178 created by further extending the -80 *creA* promoter-GFP fragment using primers  
179 pMQ80\_GFP\_R and PP3667-80\_NheI (5'-  
180 AATGCTAGCATTCCAGGTCGGATAGATACAAAAGTGTCTCGTTCGGT-3'). The  
181 -80 *creA* promoter-GFP fusion fragment was digested with NheI and HindIII restriction  
182 enzymes and ligated into similarly cut pMQ80. All plasmids were propagated in *E. coli*  
183 DH5 $\alpha$ , purified, and electroporated into *P. putida* KT2440 for induction assays.

184 Each plasmid encoding the *creA* promoter-*gfp* fusion, full or truncated, was  
185 electroporated into *P. putida* KT2440 wild type or  $\Delta$ *cahR* for transcriptional induction  
186 assays. To test metabolite-specific induction using the full *creA* promoter *gfp* reporter



187 construct, *P. putida* KT2440 wild type and  $\Delta cahR$  carrying the pMQ80:*creA*-195*gfp* plasmid  
188 were grown overnight in 1x MOPS media amended with 25 mM pyruvate, 5 mM arginine,  
189 and 20  $\mu$ g/ml gentamicin. Overnight cultures were adjusted to a uniform OD<sub>600</sub> and added  
190 to 1xMOPS media amended with 20 mM pyruvate, 20  $\mu$ g/ml gentamicin, and +/- 2 mM of  
191 each nitrogen containing compound to a final OD<sub>600</sub> of 0.5 in a 48-well plate. The  
192 compounds creatine, creatinine, sarcosine, and glycine betaine were tested for their *cahR*-  
193 dependent induction via the *creA* promoter. Plates were incubated at 30 °C with periodic  
194 shaking for 18 hours with readings of the OD<sub>600</sub> and GFP fluorescence (Excitation: 485  
195 nm/Emission: 528 nm) taken every hour.

196 To determine the region of the *creA* promoter essential for creatine-responsive  
197 *cahR*-dependent induction, induction assays using *creA-gfp* transcriptional reporters  
198 engineered with truncated regions of the *creA* promoter upstream of *gfp* were conducted.  
199 The assays were conducted as described above with the following adjustments; *P. putida*  
200 KT2440 wild type strains carrying the pMQ80:*creA*-195-*gfp*, pMQ80:*creA*-169-*gfp*,  
201 pMQ80:*creA*-80-*gfp*, or pMQ80:*creA*-56-*gfp* plasmids were induced in 1xMOPS media  
202 amended with 20 mM pyruvate, 20  $\mu$ g/ml gentamicin, and with or without 2 mM creatine.  
203 The full (-195) and -169 *creA* promoters were tested for *cahR*-dependence by measuring  
204 the transcriptional induction of *gfp* carried on the respective reporter plasmid in the *P.*  
205 *putida* KT2440  $\Delta cahR$  background. Fold induction was reported using the equation: Fold  
206 Induction = (Fluorescence Units<sub>2mM N-source</sub>/Fluorescence Units<sub>0mM nitrogen</sub>).

207

#### 208 MBP-CahR fusion protein expression and affinity purification

209 A maltose binding protein-CahR fusion (MBP-CahR) was engineered in the  
210 pMALc2x vector as previously described<sup>(13), (25), (26)</sup>. Briefly, the coding region of *cahR*

211 was amplified with primers PP\_3665Exp2ndMet\_EcoRI (5'-  
212 AAAGAATTCGTCCACCCCGCTTCTGCAAAC-3') and PP\_3665ExpR\_HindIII (5'-  
213 AAACAAGCTTAATGCCAATACCTGACCCAA-3'). The ~1 kb fragment was then  
214 digested with restriction enzymes EcoRI and HindIII (New England Biolabs, Ipswich  
215 MA), purified using Fisher's GeneJET Gel Extraction and DNA Clean Up Kit  
216 (ThermoFisher Scientific, Waltham, MA), and ligated into the similarly cut pMALc2x  
217 vector downstream of the MBP coding region. Cloning and propagation of the  
218 pMALc2x:MBP-CahR vector was carried out in *E. coli* DH5 $\alpha$  cells grown in LB broth  
219 supplemented with 150  $\mu$ g/ml carbenicillin. The pMALc2x:MBP-CahR vector was then  
220 transformed into *E. coli* T7 cells, a strain engineered to support protein expression.

221 Expression and purification of MBP-CahR was conducted as previously described  
222 for MBP-tagged GATR family regulators <sup>(13), (25), (26)</sup>. Briefly, *E. coli* T7 cells carrying the  
223 pMALc2x:MBP-CahR plasmid were grown in a 50 ml volume of LB broth supplemented  
224 with 150  $\mu$ g/ml carbenicillin, shaking at 170 rpm at 37 °C for 3 hours. Protein expression  
225 was induced by addition of isopropyl- $\beta$ -D- thiogalactopyranose (IPTG) to 1 mM followed  
226 by an additional 3 hours of growth. Cells were collected by centrifugation, frozen at -20  
227 °C overnight, thawed, and brought up in 4 ml lysis buffer per 1 gram of cells (lysis buffer:  
228 20 mM Tris HCl pH 7.4, 1 mM EDTA, 200 mM NaCl, 1x Halt protease inhibitor (Thermo),  
229 3 mg/ml lysozyme). After a 20-minute incubation to allow for lysis, an additional 5  
230 volumes of lysis buffer was added to further dilute the lysate. Cell lysates were clarified by  
231 centrifugation (20 min, 21,000 x g at 4 °C) and applied to an amylose resin column. After  
232 application of lysate, the column was washed with 10x the resin bed volume with wash  
233 buffer (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 1 mM EDTA) and the protein was eluted  
234 using one resin bed volume of elution buffer (20 mM Tris-HCl pH 7.4, 350 mM NaCl, 1

235 mM EDTA, 10 mM maltose). Expression and purification of MBP-CahR fusion protein  
236 was visualized via Coomassie staining of SDS-PAGE gels and protein concentration of the  
237 eluate was measured by UV absorbance on a Nanodrop spectrophotometer. Aliquots of  
238 protein were stored at -80 °C in 20% glycerol for future use in electrophoretic mobility  
239 shift assays (EMSAs).

240

#### 241 Electrophoretic Mobility Shift Assays (EMSAs)

242 Electrophoretic mobility shift assays (EMSAs) using MBP-CahR protein and a  
243 biotinylated promoter probes were conducted as previously described for related GATR  
244 family regulators <sup>(25)</sup>. The promoter regions of several genes predicted to be involved in  
245 creatine metabolism were amplified with 5'-biotinylation using the primers noted:  
246 *creA/PP\_3665* (CreatinaseProm\_F\_biotin 5'-5'/Biosg/GGTCTTGGGCATTTGCATGG-  
247 3' and CreatinaseProm\_R 5'-GTTTGTCCGAGACTTTGTGGC-3'); *glyA1/PP\_0297*  
248 (PP\_0297\_F\_biotin 5'-5'/Biosg/CAGTACGGAACGGGTCGTAT-3' and PP\_0297\_R 5'-  
249 GGGTAGCTGCTAGGCTCAAA-3'); and *tdcG-I/PP\_0322* (PP\_3022\_F\_biotin 5'-  
250 5'/Biosg/AAACCATCGATTCAGCACTTG-3' and PP\_3022\_R 5'-  
251 CCTTTGTGGCGATGTTATGA-3'). An additional probe consisting of the promoter  
252 region of the *atoA/PP\_3122* gene, which is unrelated to creatine metabolism, was tested as  
253 a negative control of CahR-promoter binding and was amplified with 5'-biotinylation using  
254 primers PP\_3122\_F\_biotin (5'-5'/Biosg/CTGGGCGAAGCTCTGGTACT-3') and  
255 PP\_3122\_R (5'-TGTTTAACCGACGAGGCTGT-3'). All probes were gel purified using  
256 GeneJET Gel Extraction and DNA Clean Up Kit (ThermoFisher). EMSA binding reactions  
257 were conducted with the changes previously described with 1 fmol/μl of probe and the  
258 replacement of poly(dI-dC) with salmon sperm DNA to a final concentration of 500 μg/ml

259 (25). Binding reactions were incubated for 40 minutes at 37 °C then run on a precast 5%  
260 TBE acrylamide gel at 4 °C for 45 minutes at 100 V (Bio-Rad). After transfer to Biodyne  
261 B Modified Nylon Membrane (ThermoFisher), biotinylated probe was visualized as per  
262 manufacturer's instructions with changes as previously described using the Pierce  
263 Lightshift Chemiluminescent EMSA kit (ThermoFisher Scientific) (25).

264

#### 265 Bacterial growth conditions and RNA preparation for RNA-Seq

266 *P. putida* KT2440 wild type and  $\Delta cahR$  overnight cultures were grown in 1x MOPS  
267 amended with 25 mM pyruvate and 5 mM arginine at 30 °C with shaking at 170 rpm.  
268 Overnight cultures were washed in 1xMOPS and adjusted to OD<sub>600</sub> = 1.0 in 1xMOPS with  
269 20 mM pyruvate, and 600  $\mu$ l of adjusted culture was added to 600  $\mu$ l pre-warmed 1xMOPS  
270 with 20 mM pyruvate +/- 2 mM creatine in a 24-well plate. Each *P. putida* strain was  
271 incubated in the +/- creatine condition in technical duplicate and biological triplicate.  
272 Cultures were incubated at 30 °C with shaking with sample collection at 1 hour via  
273 centrifugation and resuspension in 600  $\mu$ l of ~60 °C RNAzol RT (Sigma-Aldrich). After  
274 lysing cells by pipetting and vortexing in RNAzol, samples were stored until processing at  
275 -80 °C. RNA was extracted and purified from these frozen samples using the RNeasy Mini  
276 Extraction Kit (Qiagen) as per the manufacturer's instructions with the following  
277 adjustments: after the initial RNA extraction, the RNA samples underwent a DNaseI  
278 treatment and an additional sequential RNeasy purification.

279

#### 280 RNA-Seq library preparation.

281 Purified total RNA samples were depleted of rRNA using the MICROBExpress  
282 Bacterial mRNA Enrichment Kit protocol (Thermofisher), concentrated via precipitation

283 and resuspension, and mRNA concentrations measured via BioAnalyzer. Precipitated and  
284 depleted mRNA samples were used for construction of Illumina-compatible single-end  
285 libraries using the NEXTFlex Rapid Directional mRNA-Seq Bundle - Barcodes 1-24  
286 (BIOO Scientific). Barcoded libraries were submitted to the Vermont Genetics Network  
287 (VGN) sequencing facility at the University of Vermont for generation of read counts via  
288 the Illumina HiSeq sequencing system. An average of 11.3 million reads per sample were  
289 generated on a HiSeq 1500/2500 single-end 85 bp run.

290

#### 291 RNA-Seq data processing and analysis.

292 Quality assessment of raw sequencing data was performed using FastQC (v0.11.6).  
293 Adapters and low-quality sequences were removed using Trim Galore! (v0.6.4) removing  
294 Illumina adapters, reads <Q20, and a minimum length of 35 bp. Transcript quantification  
295 was performed using Rockhopper2 using the default parameters with verbose output.  
296 Reads from each sample were mapped to the reference genome of *Pseudomonas*  
297 *putida* strain KT2440 pre-packed with the program.

298 Differential abundance was calculated using DESeq2 by Group, a feature  
299 encompassing genotype and treatment (i.e., WT Creatine treatment vs WT without  
300 Nitrogen). Raw counts were adjusted for library size and genes with fewer than 10 counts  
301 in at least 2 samples were removed from further analysis. Normalization was performed  
302 using the default settings of DESeq2 with independent filtering and alpha (FDR) set to  
303 <0.05. Genes displaying greater than a 2-fold log<sub>2</sub> change in transcript levels between  
304 conditions were considered differentially expressed and those with a *p*-value of less than  
305 0.05 were considered significant. Gene expression data is available in the NCBI GEO  
306 database under accession GSE163362.

307

308 Phylogenetic Tree Building.

309           The amino acid FASTA sequences of orthologs of CreA (creatinase) and associated  
310 CahR orthologs (GATR-subfamily AraC members) were compiled via the STRING  
311 protein database and BLAST protein searches conducted using the National Centers for  
312 Biotechnology Information database (27), (28), (29), (30), (31), (32), (33), (34), (35), (36), (37, 38). Sequences  
313 were entered into a phylogenetic tree-building pipeline available on phylogeny.lirmm.fr  
314 (39). This pipeline uses FASTA protein sequences to create a neighbor joining  
315 phylogenetic tree using MUSCLE for sequence alignment and PhyML software for tree  
316 building. The sequences of a creatinase and GATR from *Psychrobacter* sp. 4Dc were used  
317 as the out-groups for their respective trees due to their distance in similarity from the  
318 majority of sequences analyzed. The accession numbers for the amino acid FASTA  
319 sequences used for CreA ortholog tree building are: WP\_193834191.1, WP\_194270409.1,  
320 WP\_086918772.1,    WP\_035989123.1,    WP\_061177555.1,    WP\_006415961.1,  
321 WP\_060239820.1,    WP\_151048639.1,    WP\_130136211.1,    EXE17292.1,  
322 WP\_187119852.1,    WP\_077520507.1,    WP\_090349497.1,    WP\_043248253.1,  
323 WP\_147810201.1, WP\_005244916.1, WP\_005244916.1, ENW47798.1, EXC04443.1,  
324 KCY15186.1, KCY60723.1, ENV39029.1, AJB50085.1, EXE17292.1, EXE77507.1,  
325 EKA71974.1, EXB17260.1, EXC10249.1, WP\_001094923.1, WP\_001094923.1,  
326 AAD52565.4, AEJ12833.1, AHC82230.1, AHC87608.1, AHZ77043.1. Accession  
327 numbers for the protein FASTA sequences of CahR orthologs associated with the above  
328 CreA sequences are: WP\_101206352.1, WP\_153168678.1, WP\_051495264.1,  
329 WP\_051453741.1, WP\_061177577.1, WP\_048994731.1, WP\_060239822.1,  
330 WP\_151048638.1,    WP\_004832906.1,    EXE17291.1,    WP\_058356168.1,

331 WP\_077520504.1, WP\_090349496.1, WP\_043248255.1, WP\_147810202.1,  
332 WP\_005244913.1, WP\_005244913.1, ENW47797.1, EXC04444.1, KCY15187.1,  
333 KCY60724.1, ENV39028.1, AJB50136.1, EXE17291.1, EXE77506.1, EKA71975.1,  
334 EXB17259.1, EXC10250.1, WP\_000941154.1, WP\_000941154.1, AEJ12829.1,  
335 AHC82227.1, AHC87605.1, AHZ77039.1.

336

## 337 RESULTS

338 Identification of *PP\_3665 (cahR)* as essential for *P. putida* KT2440 utilization of creatine  
339 as a sole nitrogen source

340 The location of the uncharacterized GATR *PP\_3665* near the *creA* gene led to the  
341 prediction that it would function to regulate creatine metabolism in *P. putida*. To test this  
342 prediction, we evaluated wild type and the  $\Delta PP_3665$  deletion strain's abilities to grow on  
343 various nitrogen sources related to creatine metabolism. After 18 hours of incubation *P.*  
344 *putida* wild type, *P. putida*  $\Delta PP_3665$ , and the complemented strain all grew equally  
345 efficiently on choline, arginine, and sarcosine as sole nitrogen sources (**Fig. 1C**). Growth  
346 of *P. putida*  $\Delta PP_3665$  on creatine was significantly lower when compared to WT and  
347 complemented strains ( $p < 0.0001$ ), showing no net growth compared to the no-nitrogen  
348 control media (**Fig. 1C**). When supplied with creatinine, the anhydrous form of creatine,  
349 as the sole source of nitrogen, all strains had lower growth compared to their growth in  
350 choline or to wild type in creatine ( $p < 0.01$ ), but growth of the *P. putida*  $\Delta PP_3665$  strain  
351 was not different than wild type in creatinine (**Fig. 1C**), suggesting general poor growth is  
352 likely due to inefficient creatinine utilization and potentially an alternate route in this strain  
353 of *P. putida*. Based on its essential role in creatine-dependent growth and as a transcription

354 regulator, we named *PP\_3665* as *cahR* (**c**reatine **a**mino**h**ydrolyase **r**egulator) and use that  
355 nomenclature for the remainder of this report.

356

### 357 CahR induces *creA* transcription in the presence of creatine

358 Compounds related to the creatine metabolic pathway were tested for their ability  
359 to induce *gfp* in a *cahR*-dependent manner from a *creA* promoter-*gfp* fusion. Significant  
360 transcriptional induction was observed in the presence of creatine, ~13 fold over the no-  
361 inducer condition ( $p < 0.0001$ ) (**Fig. 2A**). Induction of the *creA* promoter in the presence of  
362 creatine was also significantly higher in wild type compared to the  $\Delta cahR$  deletion strain,  
363 in which fluorescence was similar to the no-inducer condition, indicating that creatine-  
364 dependent transcription induction from the *creA* promoter is *cahR*-dependent and CahR  
365 functions as a transcriptional activator.

366 A closer look at induction of the *creA* promoter in the weakly-inducing conditions  
367 shows that glycine betaine represses expression independent of *cahR*, while creatinine  
368 mildly induces the reporter in a *cahR*-dependent manner (**Fig. 2B**). The creatinine data  
369 suggest that creatinine might interact with CahR poorly but in a manner that stimulates  
370 transcriptional induction or that our commercial creatinine has trace amounts of creatine  
371 contamination. Glycine betaine suppression of the *creA* promoter is similar to GbdR-  
372 dependent suppression of alternate GATR-controlled loci in *P. aeruginosa* <sup>(13,40)</sup>.

373 The transcriptional response of the *creA* promoter to creatine is specific and rapid  
374 as assessed during a fluorescence time course. *creA* reporter induction is only seen in WT  
375 in the presence of creatine, with normalized reporter activity peaking about four hours after  
376 addition of creatine (**Fig. 2C**). It is important to note that the activity of the reporter lags



377 native *creA* transcript accumulation, which we assessed by RT-PCR as peaking roughly at  
378 one hour post induction (data not shown).

379

### 380 CahR binds the upstream regulatory region of *creA*

381 MBP-CahR binds to the promoter region of *creA*, shifting the *creA* promoter probe  
382 in a concentration-dependent manner, but not substantially shifting the non-specific *P.*  
383 *aeruginosa atoA* promoter probe or the creatine metabolism-related genes *glyA-1* and *tdcG-*  
384 *I* (**Fig. 3**). GATR family regulators are often poorly soluble and while we have purified and  
385 examined some without epitope tagging<sup>(40,41)</sup>, fusion of maltose-binding protein (MBP) to  
386 the amino terminus greatly enhances solubility and does not alter DNA binding site  
387 specificity for other GATR family members<sup>(13, 25, 40-42)</sup>. Additionally, from those same  
388 studies and including those without epitope tags, ligand binding does not alter GATR  
389 association with DNA, a property we also confirmed with CahR (data not shown).

390

### 391 Identification of the CahR binding site in the *creA* promoter

392 *cahR*-dependent transcriptional induction of the *creA* promoter is highest when the  
393 full promoter region (between -10 bp and -195 bp from the predicted transcriptional start  
394 site) is present. When the promoter is truncated to include only -169 bp upstream of the  
395 predicted transcriptional start, transcriptional induction drops substantially compared to the  
396 full-length construct and is only ~40% higher than the uninduced condition (**Fig. 4A**).  
397 Truncations of the *creA* promoter to -80 bp or beyond eliminate all creatine-dependent  
398 transcriptional induction of the *creA* reporter. The creatine-dependent induction of the -195  
399 bp and -169 bp reporters is also *cahR*-dependent, with a significant difference in fold

400 induction observed between the reporters in the *P. putida* wild type and  $\Delta$ *cahR* strains (-  
401 195 bp  $p < 0.0001$ , -169 bp  $p < 0.001$ ) (**Fig. 4B**).

402

403 CahR is required for transcription of creatine and sarcosine metabolism-related genes in  
404 *P. putida* in response to creatine.

405 To determine the genes involved creatine utilization by *P. putida*, wild type was  
406 exposed to 2 mM creatine or 0 mM creatine in nitrogen-free minimal media for 1 hour.  
407 There were 22 transcripts differentially induced more than 4-fold in the 2 mM creatine  
408 condition compared to the 0 mM creatine control condition, the majority of which are  
409 predicted to be involved in creatine and sarcosine metabolism (**Fig. 5 and Table 1**). The  
410 gene with the highest induction over the control condition, 1260-fold, is *PP\_3667/creA*  
411 which encodes the known *P. putida* creatinase. The other member of the *creA*-containing  
412 operon, *PP\_3666* encoding a putative metabolite MFS transporter, was also among the  
413 creatine-responsive genes, induced 362 fold (**Fig. 5A and Table 1**).

414 It was not surprising that the creatinase gene was the most highly expressed gene  
415 in the presence of creatine, as lysis of creatine into urea and sarcosine is generally the first  
416 step in bacterial creatine metabolism. The predicted pathway of *P. putida* creatine  
417 metabolism is outlined in **Fig. 1A** and is supported by our differential expression data.  
418 Following the hydrolysis of urea from creatine, the resulting sarcosine molecule is  
419 oxidatively demethylated into glycine and formaldehyde by the tetrameric sarcosine  
420 oxidase encoded by *soxBDAG*. The *sox* operon *soxBDAG* genes are differentially induced  
421 between 64 and 128 fold in 2 mM creatine over the control condition. The glycine that  
422 results from sarcosine oxidation can then be converted to serine via the glycine  
423 hydroxymethyltransferase encoded by *glyA-I*, which is expressed approximately 256 fold

424 in 2 mM creatine over the control condition. Finally, serine can be converted into pyruvate  
425 via serine dehydratase encoded by the *tdcG-I* gene (ortholog of *P. aeruginosa sdaB*) that  
426 is expressed 256 fold higher in the 2 mM creatine as compared to the control. The pyruvate  
427 generated from creatine metabolism is then available for conversion into acetyl-CoA and  
428 thus into central metabolism. Taken together, the induction of creatine and sarcosine-  
429 metabolic genes provides support for the previously predicted pathway of creatine  
430 metabolism in *P. putida* KT2440 (**Fig. 1A**).

431 The role of CahR in creatine-responsive gene induction was also elucidated using  
432 RNA-seq and differential expression analysis. The 2 mM creatine versus 0 mM creatine  
433 comparison was repeated as above, but with the  $\Delta$ *cahR* mutant. When the  $\Delta$ *cahR* mutant  
434 was exposed to 2 mM creatine, the creatine and sarcosine-metabolic genes were no longer  
435 differentially expressed over the control condition, leaving only a single gene that met the  
436 cut-off criteria used for wild type – the nitrogen fixation-related gene, *fixG*. The lack of  
437 creatine metabolic gene induction in the absence of *cahR* indicates that CahR is responsible  
438 for the transcription of these genes. The lack of induction of the genes encoding  
439 downstream metabolic steps, including sarcosine oxidation in the absence of evidence for  
440 their direct control by CahR (see **Fig. 3**), is not surprising as production of sarcosine is  
441 dependent upon a CahR-regulated step. We also confirmed that creatine does not induce a  
442 *sox* operon transcriptional reporter in the absence of *creA* (data not shown). Complete  
443 RNA-Seq data is available at (NCBI GEO Accession currently in submission).

444

445 *creA* orthologs associated with a *cahR* ortholog are scattered throughout the  $\alpha$ - and  $\beta$ -  
446 proteobacteria

447 Orthologs of the *creA* creatinase cluster into two clades, one with the *P. putida* and  
448 related Pseudomonads and the other with  $\beta$ -proteobacteria and *Acinetobacter* (**Fig. 6**). A  
449 number of *Acinetobacter* species maintain a genomic region that is orthologous to *P.*  
450 *knackmussii*, *P. oryzae*, and Burkholderia creatinase-coding regions but is present flanked  
451 by transposable element boundaries. For some strains this creatinase-containing transposon  
452 is on the chromosome whereas in three others, it is plasmid-borne. The presence of  
453 creatine-metabolic genes on a transposon maintained in pathogenic bacteria suggests that  
454 creatine metabolism may be beneficial during pathogenesis. The presence of creatinase and  
455 related metabolic genes in both environmental and pathogenic species suggests a role in  
456 both niches, but the strain specific carriage of these genes and alternate gene organization  
457 in otherwise closely related species strongly suggests that these genes are readily acquired  
458 via horizontal gene transfer.

459

## 460 **DISCUSSION**

461 Creatine is a nitrogen-rich compound (N:C ratio 1:1) present in many of the  
462 ecological niches occupied by *Pseudomonas* species. The best described creatine pool is  
463 found within vertebrate muscle cells, where it participates in the rapid recharging of ADP  
464 to ATP through a direct phosphate transfer cycle. The body is constantly recycling its  
465 creatine stores and excreting creatine into the surrounding environment through urine and  
466 feces <sup>(15), (16), (17), (18)</sup>. Most of the creatine in the body is non-enzymatically converted into  
467 creatinine before excretion, making this cyclic form of creatine abundantly present in the  
468 colon, where gut-resident microbes degrade it, and the rhizosphere where it can be utilized

469 by soil-dwelling microorganisms<sup>(18), (43), (44), (45)</sup>. Because of the conversion of creatine to  
470 creatinine within vertebrates before excretion, many bacterial pathways for creatine  
471 metabolism begin with lysis of creatinine via creatinine amidohydrolase enzymes<sup>(45), (46),</sup>  
472<sup>(47), (48)</sup> (**Fig. 1A**). However, the existence of creatine-responsive metabolic genes in  
473 primarily soil dwelling bacteria that lack a creatininase suggest that creatine is available  
474 within the rhizosphere for utilization. Free creatine may come from a variety of sources,  
475 including creatinine breakdown by creatininase-possessing microbes, the in situ  
476 degradation of creatine-containing animal tissues, or excretion of smaller amounts of  
477 creatine in animal urine. Regardless of the source, the ability to metabolize creatine would  
478 enable bacteria to access a rich nitrogen source and in some cases an alternative source of  
479 carbon<sup>(10), (49)</sup>. This manuscript describes identification of a creatine-responsive  
480 transcription regulator, CahR, in *P. putida* that is critical for utilization of creatine as a sole  
481 nitrogen source.

482

483 *cahR* is essential for creatine-dependent induction of *P. putida* creatine utilization genes,  
484 thus growth on creatine as a sole nitrogen source.

485 The AraC/XylS-family of transcriptional regulators are a diverse family generally  
486 characterized by a helix-turn-helix (HTH) DNA binding C-terminal domain and an N-  
487 terminal domain dedicated to dimerization and/or ligand binding<sup>(50)</sup>. The creatine-  
488 responsive transcriptional regulator of *P. putida*, CahR, belongs to a subset of AraC/XylS-  
489 family regulators that contain a glutamine amidotransferase-1 (GATase) domain in the N-  
490 terminal region with structural similarity to the DJ-1/ThiJ/PfpI superfamily of proteins.  
491 Members of this superfamily include the human DJ-1 protein, involved in muscular  
492 dystrophy<sup>(51, 52)</sup>, and the bacterial ThiJ proteins involved in bacterial thiamine biosynthesis

493 <sup>(53)</sup>. Bacterial AraC-family transcriptional regulators in the GATase subfamily have a  
494 predicted catalytically-inactive ThiJ-like domain in the N-terminus, but that often includes  
495 a conserved cysteine residue found in the catalytic domain of active bacterial GATase  
496 proteins such as *Klebsiella pneumoniae*'s ThiJ <sup>(54), (41), (53)</sup>. Members of the GATase 1-  
497 containing AraC transcriptional regulator (GATR) family have been identified in multiple  
498 Gram-negative and Gram-positive bacteria, including *Pseudomonas* species, although  
499 functions have only been described for a limited subset of these regulators. Several of the  
500 characterized GATRs in *P. aeruginosa* participate in metabolic regulation of amine-  
501 containing compounds like arginine, glycine betaine, sarcosine, and carnitine <sup>(13), (25), (55),</sup>  
502 <sup>(56), (57, 58)</sup>. The *P. putida* GATR described in this manuscript, CahR, controls the  
503 metabolism of the amine-containing compound creatine via transcriptional induction of the  
504 creatinase CreA.

505         The participation and necessity of *cahR* in creatine metabolism is demonstrated in  
506 **Fig. 1C**, where deletion of *cahR* results in the inability of *P. putida* to grow on creatine as  
507 the sole nitrogen source. CahR binds with specificity to the promoter region of *creA* (**Fig.**  
508 **3**), from which we conclude direct transcriptional induction of *creA*, which encodes a  
509 creatinase with the ability to efficiently cleave creatine into sarcosine and urea <sup>(5), (6), (7), (8),</sup>  
510 <sup>(9), (59), (60), (61)</sup>. Transcription of *creA* occurs quickly in wild type *P. putida*, detectable by  
511 GFP reporter within 1 hour after exposure to creatine, and with rapid increase over the first  
512 5 hours post-exposure (**Fig. 2C**). At one hour post creatine exposure, a  $\approx 1260$  fold-change  
513 in transcript levels of *creA* is observed in *P. putida* WT in the presence of creatine versus  
514 a pyruvate control (**Fig 5** and **Table 1**). This suggests that lysis of creatine by CreA is the  
515 preferential pathway of *P. putida* creatine metabolism and the rapidity of creatine  
516 metabolic induction compared to rates for other GATRs suggests that creatine utilization

517 is likely a beneficial metabolic strategy for *P. putida* and/or that creatine is a resource under  
518 strong competition.

519 The metabolism of creatine by *P. putida* creatinase to the intermediate sarcosine  
520 has been observed by multiple groups and is supported by the strong transcriptional  
521 induction of the predicted sarcosine metabolic genes, orthologous to *Pseudomonas*  
522 *aeruginosa*'s *soxBDAG*, one hour post creatine exposure in *P. putida* KT2440 (**Fig. 5** and  
523 **Table 1**)<sup>(5), (6), (7), (8), (9), (59), (60), (61)</sup>. Genes involved in the subsequent steps of sarcosine  
524 metabolism, including *glyAI* encoding the serine hydroxymethyltransferase and *tdcG-I*  
525 encoding the L-serine dehydratase, are amongst the next most highly transcribed genes in  
526 the presence of creatine (**Fig 5** and **Table 1**), providing a more complete picture of creatine  
527 metabolism in *P. putida* KT2440, as outlined in **Fig. 1A**. Although multiple genes are  
528 induced in the presence of creatine, CahR specifically binds to the promoter region of *creA*  
529 alone and not to the promoter regions of the other metabolic genes most highly induced in  
530 the presence of creatine, suggesting a small creatine-specific regulon controlled by CahR  
531 (**Fig. 3**). Based on promoter mapping, CahR's specific binding site lies within region -195  
532 bp to -169 bp from the predicted transcriptional start of *creA* and likely close to or partially  
533 overlapping the -169 position. Unfortunately, CahR's apparent specificity for a single  
534 promoter prevented further prediction of a specific CahR binding site, as there is no  
535 additional promoter(s) bound by CahR to use in identifying conserved half site sequences.  
536 We did attempt alignments and motif detection between strains and species and also did  
537 not identify a potential conserved CahR binding site.

538 While *P. putida* KT2440 is able to utilize creatine and the downstream metabolite  
539 sarcosine as sole nitrogen sources, it grows poorly on creatinine (**Fig. 1C**). This is  
540 interesting, as creatinine is generally considered a precursor to creatine in the context of

541 bacterial metabolism (**Fig. 1A**). However, creatine may or may not be an intermediate in  
542 creatinine metabolism in *P. putida* KT2440, as there are alternatives in some *P. putida*  
543 strains including creatinine metabolism via N-methylhydantoin and N-carbamoylsarcosine  
544 intermediates<sup>(46)</sup>. Thus, the poor *P. putida* KT2440 growth on creatinine as a sole nitrogen  
545 source, independent of CahR-dependent creatinase induction, may be due to inefficient  
546 creatinine utilization via an intermediate that is not creatine <sup>(46), (62)</sup>. The hypothesis that  
547 creatinine, when available, is converted by *P. putida* KT2440 into an intermediate that is  
548 not creatine, such as N-methylhydantoin, is also supported by the negligible induction of  
549 *creA* in the presence of creatinine (**Fig. 2A-B**). Creatinine metabolism by a non-creatine  
550 intermediate is also supported by the observation that *P. putida* KT2440 does not appear  
551 to encode any predicted creatinine amidohydrolases, while several other strains of *P.*  
552 *putida*, including strain S16 (CP002870.1), DLL-E4 (CP007620.1), HB3267  
553 (CP003738.1), and RS56 (AF170566.3) encode creatininases transcribed divergently from  
554 *cahR* and *creA* orthologs (**Fig. 6**). The evidence for creatininase function was demonstrated  
555 using the cloned and purified enzyme from *P. putida* strain RS56 <sup>(63)</sup>. In addition to the *P.*  
556 *putida* strains that encode both creatininases and creatinases, there are several *P. monteilii*  
557 strains, a close relative of *P. putida*, which share syntentic creatininase/creatinase genomic  
558 regions, including *P. monteilii* SB3101 (CP006979.1) and SB3078 (CP006978.1). *P.*  
559 *monteilii* has been implicated in several opportunistic infections, while *P. putida* HB3267,  
560 a strain isolated from hospitalized patients and also contains this gene arrangement, shows  
561 cytolytic activity against human cells<sup>(64),(65)</sup>.

562 It is also interesting to note that glycine betaine inhibits basal transcription of *creA*  
563 independent of CahR. This may be indicative of an inhibitory feedback mechanism  
564 perpetuated by downstream products of creatine metabolism or the direct or tangential



565 involvement of other compound-specific regulators in creatine metabolism. In *P.*  
566 *aeruginosa*, the glycine betaine/dimethylglycine sensing regulator GbdR is able to repress  
567 activation from promoters co-regulated with other GATR family members when glycine  
568 betaine is present, best described at the carnitine operon promoter that is induced in a  
569 carnitine-dependent manner by the GATR member CdhR<sup>(40)</sup>. Increased transcription of  
570 GbdR and glycine betaine metabolic genes is also observed in wild type *P. putida* KT2440  
571 in the presence of creatine, which supports potential interplay between *P. putida* GATRs  
572 (**Fig 5**).

573

574 Conservation of *creA* and *cahR* synteny illustrate the potential utility of this genetic  
575 module in creatine rich environments

576 Pathways for creatinine and creatine metabolism are conserved among diverse  
577 bacteria. Examining sequence similarity and genomic organization between bacteria, the  
578 presence of a CahR-regulated creatine-inducible creatinase appears to be conserved among  
579 several species, based on the presence of *creA* orthologs co-occurring with predicted *cahR*  
580 orthologs in similar genomic organization as *P. putida* (genomic organization in *P. putida*  
581 KT2440 shown in **Fig. 1B**). The phylogenetic tree in **Fig. 6** is for CreA, while a tree of the  
582 associated CahR orthologs has a very similar topology but, as expected for a regulator  
583 compared to an enzyme, shows substantially longer branch lengths (data not shown).

584 The presence of a *creA* ortholog with an associated *cahR* ortholog in a limited  
585 number of strains within a given species supports a model of horizontal gene transfer of  
586 creatinase-responsive metabolic genes between bacteria. The case of *cahR* and *creA*  
587 orthologs among *Acinetobacter* species provides the most compelling support for  
588 horizontal transfer of *cahR* and *creA*. The clade with the shortest branch lengths consists

589 exclusively of *Acinetobacter* species, including *A. baumannii*, *A. nosocomalis*, and *A. pittii*.  
590 These *Acinetobacter* species are members of the *Acinetobacter calcoaceticus*-  
591 *Acinetobacter baumannii* complex (ACB) and are known for their ability to cause  
592 persistent, multidrug resistant, nosocomial infections in humans<sup>(66),(67)</sup>. Of the  
593 *Acinetobacter* isolates possessing *cahR/creA* orthologs, several were isolated from urine,  
594 which is the primary vehicle of creatine excretion in animals<sup>[8]</sup>. Additionally, all of the  
595 *Acinetobacter* clinical isolates analyzed possess *cahR/creA* orthologs flanked by  
596 transposon or integrase flanking sequences, suggesting that the creatine-responsive  
597 creatine-metabolic enzymes are part of a transposable element horizontally transferred  
598 amongst pathogenic *Acinetobacter* species.

599         The majority of the *cahR/creA*-containing transposons present in the *Acinetobacter*  
600 species are identical, containing *cahR*, *creA*, and *PP\_3666* (encoding the MFS transporter)  
601 flanked by transposase/integrase flanking regions, while several species include additional  
602 genes related to creatine metabolism such as urease genes, within the putative transposable  
603 element (**Fig 6**). In three cases, the *cahR/creA*-containing transposon is present on a  
604 plasmid that is maintained by *Acinetobacter*. The strains possessing these plasmids, *A.*  
605 *baumannii* AYE (SAMEA3138279), *A. pittii* AP43 (SAMN12612836), and *A.*  
606 *nosocomalis* 6411 (SAMN03263968), cluster together (**Fig 6**). The AP43 plasmid also  
607 carries virulence factor *blaNDM-1*, which confers resistance to carbapenems and  
608 cephalosporins, while AYE is associated with MDR community-acquired infections<sup>(68)</sup>.  
609 The maintenance of the *cahR/creA* orthologs, both on plasmids and within transposable  
610 elements, suggests that these genes were likely acquired from other sources, such as  
611 *cahR/creA*-possessing gut microbiome members *Vitreoscilla massiliensis* or *Thauera* 2A1,  
612 or from one of the many environmental or opportunistic pathogen species that share

613 *Acinetobacter*'s niches<sup>(69),(70)</sup>. While the existence of *cahR/creA*-containing transposons  
614 and plasmids suggest that acquisition and maintenance of these genes is advantageous to  
615 *Acinetobacter*'s lifestyle, the potential benefits of this region for bacterial survival and  
616 virulence have yet to be evaluated.

617

## 618 Conclusions

619 Here we have described the identification of a creatine-responsive transcription  
620 regulator, CahR, that is necessary for creatine utilization by regulating creatinase gene  
621 induction. There are a number of issues raised by the data presented here that remain to be  
622 explored. Based on our count this is now the fourth GATR for which an inducing ligand is  
623 known, yet we still do not understand how ligands are bound and how specificity is  
624 determined. These GATRs all control organic nitrogen compound utilization and are likely  
625 not-so-ancient paralogs that diversified for specialization to structurally related but  
626 different small molecules. Thus, the GATRs might provide a good model to understand the  
627 evolution of substrate specificity for transcription regulators. Finally, the ecological and/or  
628 virulence function for creatine metabolism and its regulation is not understood. The  
629 obvious horizontal gene transfer of this metabolic system in *Acinetobacter* might offer a  
630 promising system to test the function of creatine metabolism and regulation in an  
631 opportunistic pathogen.

632

## 633 **Acknowledgements:**

634 We would like to thank Alexis Nadeau for technical assistance during their research  
635 rotation. The next-generation sequencing and bioinformatic analysis was performed in the  
636 Vermont Integrative Genomics Resource Massively Parallel Sequencing Facility and was

637 supported by the University of Vermont Cancer Center, Lake Champlain Cancer Research  
638 Organization, UVM College of Agriculture and Life Sciences, and the UVM Larner  
639 College of Medicine. This work was supported in part by R21AI137453 and internal  
640 funding from the Larner College of Medicine to MJW. LAH was supported by T32  
641 AI055402.

## 642 REFERENCES

- 643 1. Loeschcke A, Thies S. *Pseudomonas putida*-a versatile host for the production of  
644 natural products. *Appl Microbiol Biotechnol*. 2015;99(15):6197-214.
- 645 2. Kivisaar M. Narrative of a versatile and adept species *Pseudomonas putida*. *J Med*  
646 *Microbiol*. 2020;69(3):324-38.
- 647 3. Winsor GL, Griffiths EJ, Lo R, Dhillon BK, Shay JA, Brinkman FS. Enhanced  
648 annotations and features for comparing thousands of *Pseudomonas* genomes in the  
649 *Pseudomonas* genome database. *Nucleic Acids Res*. 2016;44(D1):D646-53.
- 650 4. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. *Physiol Rev*.  
651 2000;80(3):1107-213.
- 652 5. Yoshimoto T, Oka I, Tsuru D. Purification, crystallization, and some properties of  
653 creatine amidinohydrolase from *Pseudomonas putida*. *J Biochem*. 1976;79(6):1381-3.
- 654 6. Afshari E, Amini-Bayat Z, Hosseinkhani S, Bakhtiari N. Cloning, Expression and  
655 Purification of *Pseudomonas putida* ATCC12633 Creatinase. *Avicenna J Med*  
656 *Biotechnol*. 2017;9(4):169-75.
- 657 7. Schumann J, Bohm G, Schumacher G, Rudolph R, Jaenicke R. Stabilization of  
658 creatinase from *Pseudomonas putida* by random mutagenesis. *Protein Sci*.  
659 1993;2(10):1612-20.
- 660 8. Appleyard G, Woods DD. The pathway of creatine catabolism by *Pseudomonas*  
661 *ovalis*. *J Gen Microbiol*. 1956;14(2):351-65.
- 662 9. Hoeffken HW, Knof SH, Bartlett PA, Huber R, Moellering H, Schumacher G.  
663 Crystal structure determination, refinement and molecular model of creatine  
664 amidinohydrolase from *Pseudomonas putida*. *J Mol Biol*. 1988;204(2):417-33.
- 665 10. Nimmo-Smith RH, Appleyard G. Studies with a *Pseudomonad* able to grow with  
666 creatine as main source of carbon and nitrogen. *J Gen Microbiol*. 1956;14(2):336-50.
- 667 11. Appleyard G. The metabolism of creatine by a *pseudomonad*. *Biochem J*.  
668 1951;49(5):lxx.
- 669 12. Beuth B, Niefind K, Schomburg D. Crystal structure of creatininase from  
670 *Pseudomonas putida*: a novel fold and a case of convergent evolution. *J Mol Biol*.  
671 2003;332(1):287-301.
- 672 13. Willsey GG, Wargo MJ. Sarcosine Catabolism in *Pseudomonas aeruginosa* Is  
673 Transcriptionally Regulated by SouR. *J Bacteriol*. 2016;198(2):301-10.
- 674 14. Harms C, Schleicher A, Collins MD, Andreesen JR. *Tissierella creatinophila* sp.  
675 nov., a gram-positive, anaerobic, non-spore-forming, creatinine-fermenting organism. *Int*  
676 *J Syst Bacteriol*. 1998;48 Pt 3:983-93.
- 677 15. Yasuhara M, Fujita S, Furukawa I, Arisue K, Kohda K, Hayashi C. Continuous-  
678 flow enzymic determination of creatine in urine. *Clin Chem*. 1981;27(11):1888-91.
- 679 16. Habibi S, Djedidi S, Ohkama-Ohtsu N, Sarhadi WA, Kojima K, Rallos RV, et al.  
680 Isolation and Screening of Indigenous Plant Growth-promoting Rhizobacteria from  
681 Different Rice Cultivars in Afghanistan Soils. *Microbes Environ*. 2019;34(4):347-55.
- 682 17. Yasuda M, Sugahara K, Zhang J, Ageta T, Nakayama K, Shuin T, et al.  
683 Simultaneous determination of creatinine, creatine, and guanidinoacetic acid in human  
684 serum and urine using liquid chromatography-atmospheric pressure chemical ionization  
685 mass spectrometry. *Anal Biochem*. 1997;253(2):231-5.
- 686 18. Skinner JJ. Beneficial effect of creatinine and creatine on growth. *Botanical*  
687 *Gazette*. 1912;2(54):152-63.

- 688 19. Neidhardt FC, Bloch PL, Smith DF. Culture medium for enterobacteria. J  
689 Bacteriol. 1974;119(3):736-47.
- 690 20. LaBauve AE, Wargo MJ. Growth and laboratory maintenance of *Pseudomonas*  
691 *aeruginosa*. Curr Protoc Microbiol. 2012;Chapter 6:Unit 6E 1.
- 692 21. Shanks RM CN, Hinsa, SM, Toutain CM, O'Toole GA. *Saccharomyces*  
693 *cerevisiae*-based molecular tool kit for manipulation of genes from gram-negative  
694 bacteria. Appl Environ Microbiol. 2006;72:5027-36.
- 695 22. Choi KH, Schweizer HP. mini-Tn7 insertion in bacteria with single attTn7 sites:  
696 example *Pseudomonas aeruginosa*. Nature protocols. 2006;1(1):153-61.
- 697 23. Choi KH, Gaynor JB, White KG, Lopez C, Bosio CM, Karkhoff-Schweizer RR,  
698 et al. A Tn7-based broad-range bacterial cloning and expression system. Nat Methods.  
699 2005;2(6):443-8.
- 700 24. Bryksin AV, Matsumura I. Overlap extension PCR cloning: a simple and reliable  
701 way to create recombinant plasmids. Biotechniques. 2010;48(6):463-5.
- 702 25. Hampel KJ, Labauve AE, Meadows JA, Fitzsimmons LF, Nock AM, Wargo MJ.  
703 Characterization of the GbdR Regulon in *Pseudomonas aeruginosa*. J Bacteriol.  
704 2014;196(1):7-15.
- 705 26. LaBauve AE, Wargo MJ. Detection of host-derived sphingosine by *Pseudomonas*  
706 *aeruginosa* is important for survival in the murine lung. PLoS pathogens.  
707 2014;10(1):e1003889.
- 708 27. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al.  
709 STRING v11: protein-protein association networks with increased coverage, supporting  
710 functional discovery in genome-wide experimental datasets. Nucleic Acids Res.  
711 2019;47(D1):D607-D13.
- 712 28. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The  
713 STRING database in 2017: quality-controlled protein-protein association networks, made  
714 broadly accessible. Nucleic Acids Res. 2017;45(D1):D362-D8.
- 715 29. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et  
716 al. STRING v10: protein-protein interaction networks, integrated over the tree of life.  
717 Nucleic Acids Res. 2015;43(Database issue):D447-52.
- 718 30. Franceschini A, Lin J, von Mering C, Jensen LJ. SVD-phy: improved prediction  
719 of protein functional associations through singular value decomposition of phylogenetic  
720 profiles. Bioinformatics. 2016;32(7):1085-7.
- 721 31. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al.  
722 STRING v9.1: protein-protein interaction networks, with increased coverage and  
723 integration. Nucleic Acids Res. 2013;41(Database issue):D808-15.
- 724 32. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguéz P, et al.  
725 The STRING database in 2011: functional interaction networks of proteins, globally  
726 integrated and scored. Nucleic Acids Res. 2011;39(Database issue):D561-8.
- 727 33. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. STRING 8--  
728 a global view on proteins and their functional interactions in 630 organisms. Nucleic  
729 Acids Res. 2009;37(Database issue):D412-6.
- 730 34. von Mering C, Jensen LJ, Kuhn M, Chaffron S, Doerks T, Kruger B, et al.  
731 STRING 7--recent developments in the integration and prediction of protein interactions.  
732 Nucleic Acids Res. 2007;35(Database issue):D358-62.
- 733 35. von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al.  
734 STRING: known and predicted protein-protein associations, integrated and transferred  
735 across organisms. Nucleic Acids Res. 2005;33(Database issue):D433-7.

- 736 36. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a  
737 database of predicted functional associations between proteins. *Nucleic Acids Res.*  
738 2003;31(1):258-61.
- 739 37. Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and  
740 display the repeatedly occurring neighbourhood of a gene. *Nucleic Acids Res.*  
741 2000;28(18):3442-4.
- 742 38. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment  
743 search tool. *J Mol Biol.* 1990;215(3):403-10.
- 744 39. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, et al.  
745 Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.*  
746 2008;36(Web Server issue):W465-9.
- 747 40. Meadows JA, Wargo MJ. Transcriptional regulation of carnitine catabolism in  
748 *Pseudomonas aeruginosa* by CdhR. *mSphere.* 2018;3(1):e00480-17.
- 749 41. Nock AM, Wargo MJ. Choline Catabolism in *Burkholderia thailandensis* Is  
750 Regulated by Multiple Glutamine Amidotransferase 1-Containing AraC Family  
751 Transcriptional Regulators. *J Bacteriol.* 2016;198(18):2503-14.
- 752 42. Wargo MJ, Ho TC, Gross MJ, Whittaker LA, Hogan DA. GbdR regulates  
753 *Pseudomonas aeruginosa plcH* and *pchP* transcription in response to choline catabolites.  
754 *Infect Immun.* 2009;77(3):1103-11.
- 755 43. Miller BF, Allinson, M. C., Baker Z. Studies on the metabolism of creatine and  
756 creatinine I. Specific Enzymatic Methods for the Analysis of Creatine and Creatinine in  
757 Tissues. *Journal of Biological Chemistry* 1939;1(130):383-91.
- 758 44. Twort FW, Mellanby, E. On creatine-destroying Bacilli in the intestine, and their  
759 isolation. *The Journal of Physiology* 1912;1-2(44):43.
- 760 45. Ito K. [Structural and functional analysis of enzymes and their application to  
761 clinical analysis--study on *Pseudomonas putida* formaldehyde dehydrogenase]. *Yakugaku*  
762 *Zasshi.* 2002;122(10):805-11.
- 763 46. Shimizu S, Kim, J. M., Shinmen, Y., Yamada, H. . Evaluation of two alternative  
764 metabolic pathways for creatine degradation in microorganisms *Archives of*  
765 *microbiology* 1986;4(145):322-8.
- 766 47. Langille MG, Meehan CJ, Koenig JE, Dhanani AS, Rose RA, Howlett SE, et al.  
767 Microbial shifts in the aging mouse gut. *Microbiome.* 2014;2(1):50.
- 768 48. Polacheck I, Kwon-Chung KJ. Creatinine metabolism in *Cryptococcus*  
769 *neoformans* and *Cryptococcus bacillisporus*. *J Bacteriol.* 1980;142(1):15-20.
- 770 49. Bendt AK, Beckers G, Silberbach M, Wittmann A, Burkovski A. Utilization of  
771 creatinine as an alternative nitrogen source in *Corynebacterium glutamicum*. *Arch*  
772 *Microbiol.* 2004;181(6):443-50.
- 773 50. Gallegos MT, Schleif R, Bairoch A, Hofmann K, Ramos JL. Arac/XylS family of  
774 transcriptional regulators. *Microbiol Mol Biol Rev.* 1997;61(4):393-410.
- 775 51. Lakshminarasimhan M, Maldonado MT, Zhou W, Fink AL, Wilson MA.  
776 Structural impact of three Parkinsonism-associated missense mutations on human DJ-1.  
777 *Biochemistry.* 2008;47(5):1381-92.
- 778 52. Jung HJ, Kim S, Kim YJ, Kim MK, Kang SG, Lee JH, et al. Dissection of the  
779 dimerization modes in the DJ-1 superfamily. *Mol Cells.* 2012;33(2):163-71.
- 780 53. Bandyopadhyay S, Cookson MR. Evolutionary and functional relationships  
781 within the DJ1 superfamily. *BMC evolutionary biology.* 2004;4:6.
- 782 54. Weng ML, Zalkin H. Structural role for a conserved region in the CTP synthetase  
783 glutamine amide transfer domain. *J Bacteriol.* 1987;169(7):3023-8.

- 784 55. Meadows JA, Wargo MJ. Transcriptional Regulation of Carnitine Catabolism in  
785 *Pseudomonas aeruginosa* by CdhR. *mSphere*. 2018;3(1).
- 786 56. Wargo MJ. Homeostasis and catabolism of choline and glycine betaine: lessons  
787 from *Pseudomonas aeruginosa*. *Appl Environ Microbiol*. 2013;79(7):2112-20.
- 788 57. Park SM, Lu CD, Abdelal AT. Cloning and characterization of argR, a gene that  
789 participates in regulation of arginine biosynthesis and catabolism in *Pseudomonas*  
790 *aeruginosa* PAO1. *Journal of bacteriology*. 1997;179(17):5300-8.
- 791 58. Lu C-D, Yang Z, Li W. Transcriptome Analysis of the ArgR Regulon in  
792 *Pseudomonas aeruginosa*. *Journal of Bacteriology*. 2004;186(12):3855-61.
- 793 59. Chang MC, Chang CC, Chang JC. Cloning of a creatinase gene from  
794 *Pseudomonas putida* in *Escherichia coli* by using an indicator plate. *Appl Environ*  
795 *Microbiol*. 1992;58(10):3437-40.
- 796 60. Hong MC, Chang JC, Wu ML, Chang MC. Expression and export of  
797 *Pseudomonas putida* NTU-8 creatinase by *Escherichia coli* using the chitinase signal  
798 sequence of *Aeromonas hydrophila*. *Biochem Genet*. 1998;36(11-12):407-15.
- 799 61. Yoshimoto T, Oka I, Tsuru D. Creatine amidinohydrolase of *Pseudomonas*  
800 *putida*: crystallization and some properties. *Arch Biochem Biophys*. 1976;177(2):508-15.
- 801 62. Ogawa J, Kim JM, Nirdnoy W, Amano Y, Yamada H, Shimizu S. Purification  
802 and characterization of an ATP-dependent amidohydrolase, N-methylhydantoin  
803 amidohydrolase, from *Pseudomonas putida* 77. *Eur J Biochem*. 1995;229(1):284-90.
- 804 63. Tang TY, Wen, C. J., Liu, W. H. Expression of the creatinase gene from  
805 *Pseudomonas putida* RS65 in *Escherichia coli* *Journal of Industrial Microbiology and*  
806 *Biotechnology* 2000;1(24):2-6.
- 807 64. Aditi, Shariff M, Beri K. Exacerbation of bronchiectasis by *Pseudomonas*  
808 *monteilii*: a case report. *BMC Infect Dis*. 2017;17(1):511-.
- 809 65. Fernández M, Porcel M, de la Torre J, Molina-Henares MA, Daddaoua A, Llamas  
810 MA, et al. Analysis of the pathogenic potential of nosocomial *Pseudomonas putida*  
811 strains. *Frontiers in microbiology*. 2015;6:871-.
- 812 66. Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of  
813 *Acinetobacter baumannii* virulence. *Nat Rev Microbiol*. 2018;16(2):91-102.
- 814 67. Knight DB, Rudin SD, Bonomo RA, Rather PN. *Acinetobacter nosocomialis*:  
815 Defining the Role of Efflux Pumps in Resistance to Antimicrobial Therapy, Surface  
816 Motility, and Biofilm Formation. *Frontiers in microbiology*. 2018;9:1902-.
- 817 68. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, et al.  
818 Comparative analysis of *Acinetobacter*s: three genomes for three lifestyles. *PLoS One*.  
819 2008;3(3):e1805-e.
- 820 69. Ndongo S, Lagier JC, Raoult D, Fournier PE. *Gorillibacterium timonense* sp. nov.  
821 and *Vitreoscilla massiliensis* sp. nov., two new bacterial species isolated from stool  
822 specimens of obese Amazonian patients. *New Microbes New Infect*. 2018;23:48-51.
- 823 70. Xu Y, Xie Z, Wang H, Shen Z, Guo Y, Gao Y, et al. Bacterial Diversity of  
824 Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA  
825 Gene Deep Sequencing. *Sci Rep*. 2017;7(1):3628-.
- 826




827 **Table 1.** Differentially expressed transcripts in wild-type cells in the absence and  
 828 presence of creatine.  
 829

Gene	log2FoldChange	log2 Mean	Product Function / Product Relationship
<i>PP_3667 creA</i>	10.3	12.5	creatinase
<i>PP_3666</i>	8.5	9.3	major facilitator superfamily transporter
<i>PP_0322 glyA-1</i>	8.3	10.7	serine hydroxymethyltransferase
<i>PP_4665</i>	8.3	8.1	PA2762 ortholog
<i>PP_0297 tdcG-1</i>	8.3	8.9	L-serine dehydratase
<i>PP_0323 soxB</i>	7.3	9.8	sarcosine oxidase subunit beta
<i>PP_0324 soxD</i>	6.9	8.4	sarcosine oxidase subunit delta
<i>PP_0325 soxA</i>	6.6	10.9	sarcosine oxidase subunit alpha
<i>PP_0326 soxG</i>	6.4	8.2	sarcosine oxidase subunit gamma
<i>PP_0327 purU-1</i>	5.1	8.8	formyltetrahydrofolate deformylase
<i>PP_4638</i>	3.7	6.3	methylenetetrahydrofolate reductase domain-containing protein
<i>PP_0895</i>	3.3	3.3	hypothetical protein
<i>PP_3526</i>	2.9	6.2	Predicted SouR ortholog
<i>PP_1617 frmC</i>	2.6	6.5	S-formylglutathione hydrolase
<i>PP_1616 frmA</i>	2.6	7.5	D-isomer specific 2-hydroxyacid dehydrogenase
<i>PP_0896</i>	2.6	3.7	C/N hydrolase; nitrilase/cyanide hydratase
<i>PP_0299</i>	2.5	6.9	Predicted GbdR ortholog
<i>PP_3543</i>	2.5	6.0	(Fe-S)-binding protein
<i>PP_2183 fdhG</i>	2.4	3.7	formate dehydrogenase subunit gamma
<i>PP_0236 ssuA</i>	2.2	3.5	NAD(P)H-dependent FMN reductase
<i>PP_0315 gbcA</i>	2.1	4.5	Rieske (2Fe-2S) domain-containing protein; GB metabolism
<i>PP_0894</i>	2.1	4.4	NTF2 family protein

830  
 831

832



833

834 **Figure 1. The creatine metabolic pathway and the role of *PP\_3665/cahR* in creatine**

835 **metabolism. (A)** The creatine metabolic pathway in *P. putida* intersects with the choline

836 metabolic pathway at sarcosine. The enzymes primarily discussed in this study are noted

837 in blue. **(B)** Genomic organization around the creatinase gene (*PP\_3667/creA*) in *P.*

838 *putida* KT2440. Gene colors match those used in Figure 6. **(C)** Net growth of *P. putida*


839 wild type (WT),  $\Delta PP_3665/cahR$  ( $\Delta$ ), and the complemented strain (C), compared to

840 nitrogen free minimal media controls. The compounds present as the sole nitrogen source

841 are listed below each group of bars. Error bars denote standard deviation from between

842 three and six experiments.

843



844

845


846 **Figure 2. Induction of a GFP transcriptional reporter to the *creA* promoter region.**

847 **(A)** Creatine strongly induces the  $P_{creA-gfp}$  reporter in wild-type cells (WT) but not in the

848  $\Delta cahR$  strain ( $\Delta$ ). Statistical significance tested using ANOVA with Sidak's post-test

849 comparing wild-type to deletion within each condition. The four asterisks represents  $p <$

850 0.0001; all other statistical comparisons are note in panel B. **(B)** Data replotted from (A)  
851 but leaving out the creatine condition to emphasize small but replicable changes driven  
852 by glycine betaine and creatinine. Statistical analysis tested using ANOVA with Sidak's  
853 post-test comparing all pairs of data. The glycine betaine condition represses expression  
854 significantly independent of *cahR* (a, denotes  $p < 0.001$  in comparison to no inducing  
855 compound). Creatinine very slightly but replicably induces the reporter (b, denotes  $p <$   
856  $0.05$  in comparison to no inducing compound), which is dependent on *cahR* (c, denotes  $p$   
857  $< 0.05$  in comparison to WT creatinine). **(C)** Timecourse of induction from the *creA*  
858 promoter in wild type (WT, filled symbols) and  $\Delta cahR$  ( $\Delta$ , open symbols) in the presence  
859 of no inducer (none), sarcosine (sarc), glycine betaine (GB), creatine (cre), and creatinine  
860 (crt). Error bars in all panels represent standard deviation.



861

862


863 **Figure 3. Electrophoretic mobility shift assays (EMSA) with purified MBP-CahR.**

864 Purified MBP-CahR (concentrations noted at bottom of each lane) was incubated with the

865 biotinylated promoter probes labeled at the top of each blot. Strong and specific shift only

866 noted with the *creA* promoter.

867




868

869

870 **Figure 4. Mapping the likely CahR binding site in the *creA* promoter.** Promoter  
871 truncations based on the  $P_{creA}$ -*gfp* reporter were used to assess the minimal fragments that  
872 retain creatine/*cahR*-dependent induction. **(A)** Fold induction of four promoter truncations  
873 in wild type cells. **(B)** Expression from the two largest promoter truncations in wild-type  
874 (WT) and the *cahR* deletion ( $\square$ ). In both panels, tan block represents the predicted  
875 promoter.

876

877



878

879 **Figure 5. Mean-difference (MD) plot of transcript abundance comparing wild type in**  
880 **creatine over wild type with no added nitrogen source.** Wild type *P. putida* KT2440  
881 was transferred to media with or without creatine as a sole nitrogen source for 1h, after  
882 which RNA was harvested and transcriptomics by RNA-Seq conducted. Transcripts that  
883 met the fold change ( $\text{Log}_2 > 2$ ) and p-value ( $p < 0.05$ ) are shown in blue and labeled where  
884 space allowed. All transcripts meeting these two qualifications are listed in **Table 1**.

